Effectiveness of Second-Line Pembrolizumab Monotherapy for the Treatment of Nonsmall Cell Lung Cancer: A Retrospective-Single Institution Study of 52 Vietnamese Patients.
Background: Our aim was to demonstrate the efficacy and safety of pembrolizumab monotherapy as second-line treatment in Vietnamese nonsmall cell lung cancer (NSCLC) patients. Methods: We performed a single-center retrospective study of patients with advanced NSCLC who received pembrolizumab as secon...
| Publicado en: | Clinical Medicine Insights: Oncology pp. 1 - 12 |
|---|---|
| Autores principales: | , , , , , , |
| Formato: | research tables/charts Journal Article |
| Publicado: |
Sage Publications Inc.
8/7/2025
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=187242318&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 187242318 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 11795549 B3KT jtl: Clinical Medicine Insights: Oncology issn: 11795549 maglogo: Y pubinfo: dt: 8/7/2025 pid: 344 pub: Sage Publications Inc. place: Thousand Oaks, California artinfo: ui: 187242318 187242318 187242318 10.1177/11795549251359142 187242318 ppf: 1 ppct: 11 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Effectiveness of Second-Line Pembrolizumab Monotherapy for the Treatment of Nonsmall Cell Lung Cancer: A Retrospective-Single Institution Study of 52 Vietnamese Patients. aug: au: Tai Nguyen, Van Kien Do, Hung Van Le, Quang Tu Do, Anh Chu Nguyen, Van Phuong Nguyen, Thi Bich Hoa Nguyen, Thi Nhu affil: Vietnam National Cancer Hospital—K Hospital, Hanoi, Vietnam sug: subj: Antibodies, Monoclonal Therapeutic Use Antineoplastic Agents Therapeutic Use Carcinoma, Non-Small-Cell Lung Drug Therapy Cancer Patients Patient Safety Treatment Outcomes Antibodies, Monoclonal Administration and Dosage Antineoplastic Agents Administration and Dosage Human Retrospective Design Vietnamese Persons Overall Survival Adenocarcinoma Descriptive Statistics Programmed Cell Death Ligand 1 Gene Expression Middle Age Aged Aged, 80 and Over Progression-Free Survival Confidence Intervals Multivariate Analysis Middle Aged: 45-64 years Aged: 65+ years Aged, 80 & over ab: Background: Our aim was to demonstrate the efficacy and safety of pembrolizumab monotherapy as second-line treatment in Vietnamese nonsmall cell lung cancer (NSCLC) patients. Methods: We performed a single-center retrospective study of patients with advanced NSCLC who received pembrolizumab as second-line therapy at the Vietnam National Cancer Hospital between January 2017 and October 2023. The primary endpoints were overall survival (OS) and tumor response. Results: A total of 52 patients were included. Adenocarcinoma was observed in 43 of 52 cases (82.7%), and 40.4% of patients had PD-L1 expression in at least 50% of tumor cells. Median body weight was 57 kg (range, 45-80), and 73.1% of patients received pembrolizumab at a dose of 100 mg/3 weeks, with a median dose of 1.9 mg/kg/3-weeks (range, 1.3-4.3). The overall response rate and disease control rate were 26.9% and 51.9%, respectively. Median PFS was 6.5 months (95% CI, 3.3-9.7), and 1-year and 2-year PFS rates were 28.5% and 15.9%, respectively. Median OS was 12.0 months (95% CI, 9.8-14.2); 1-year, 2-year, and 3-year OS rates were 53.1%, 22.3%, and 8.5%, respectively. ECOG status and number of organs metastases were significantly associated with PFS and OS in the multivariate analysis. No adverse events of grades 3 to 4 were reported during the treatment. Conclusions: Second-line pembrolizumab has a good disease control rate and prolonged survival and is a viable option for the treatment of Vietnamese NSCLC patients. Further clinical studies are necessary to determine the effectiveness of administering a low dose of pembrolizumab in this setting, particularly in Asian population. pubtype: Academic Journal doctype: research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|